Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMX-020 for lumbosacral radiculopathy pain
ACTRN12615000885594Phase 2Completed
- Sponsor
- Cytometix
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CMX-020 in lumbosacral radiculopathy and chronic pain (2 arms), sponsored by Cytometix. Primary endpoint: Change in daily worst leg pain. Started Aug 2015; status: completed.
02
Drugs
CMX-020
03
Conditions
lumbosacral radiculopathychronic pain
Beyond the preview
Go deeper on ACTRN12615000885594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000885594.